Key terms
About ANNX
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington’s and alzheimer’s disease, multiple sclerosis, glaucoma, parkinson’s disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ANNX news
Yesterday
4:57am ET
Anticipating Growth: Positive Outlook for Annexon Biosciences Amid Upcoming Clinical Trials and New Data Readouts
Mar 27
6:16am ET
Annexon price target raised to $12 from $11 at Wells Fargo
Mar 26
10:25pm ET
Annexon Biosciences (ANNX) Receives a Buy from TD Cowen
Mar 26
5:12pm ET
Annexon files $400M mixed securities shelf
Mar 26
4:09pm ET
Annexon reports Q4 EPS (36c), consensus (44c)
Mar 25
2:05pm ET
Annexon options imply 24.7% move in share price post-earnings
Mar 25
1:15pm ET
Annexon participates in a conference call with JPMorgan
Mar 25
11:44am ET
Annexon participates in a conference call with JPMorgan
Mar 04
5:44pm ET
Annexon Biosciences Hosts Virtual R&D Day Event
Mar 01
4:59am ET
Annexon upgraded to Overweight from Neutral at JPMorgan
Mar 01
4:31am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Argenx Se (ARGX), GoodRx Holdings (GDRX) and Annexon Biosciences (ANNX)
Dec 28
4:44pm ET
Annexon director buys $1.0M in common stock
Dec 28
4:44pm ET
Annexon director buys $1.0M in common stock
No recent news articles are available for ANNX
No recent press releases are available for ANNX
ANNX Financials
Key terms
Ad Feedback
ANNX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ANNX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range